# A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects

> **NCT05294458** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 10 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis
- Type 2 Diabetes Mellitus (T2DM)
- Chronic Kidney Disease

## Interventions

- **DRUG:** cotadutide solution for injection

## Key facts

- **NCT ID:** NCT05294458
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-28
- **Primary completion:** 2022-09-12
- **Final completion:** 2022-09-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05294458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05294458, "A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05294458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*